Althunayyan Aeshah, Petersen Steffen E, Lloyd Guy, Bhattacharyya Sanjeev
a Barts Heart Centre, St Bartholomew's Hospital , Barts Health NHS Trust , London , UK.
b William Harvey Research Institute , Queen Mary University of London , London , UK.
Expert Rev Cardiovasc Ther. 2019 Jan;17(1):43-51. doi: 10.1080/14779072.2019.1553619. Epub 2018 Dec 3.
: Mitral valve prolapse (MVP) is a common valve pathology with a spectrum of disease from isolated prolapse to myxomatous, multi-scallop Barlow's disease. The main complications relate to progression of mitral regurgitation, endocarditis, sudden death, and stroke. The timing of intervention in patients with asymptomatic severe mitral regurgitation is controversial. : This article reviews the pathophysiology, genetics, clinical features, diagnostic imaging, complications, long-term outcomes, and indications for intervention in MVP. : Several key dilemmas in the management of MVP remain. Factors which influence progression of mitral regurgitation are unclear and therefore, we have no therapeutic targets to prevent progression. Evidence-based methods to reduce the risk of sudden death, stroke, and endocarditis have not been identified. In symptomatic patients with severe mitral regurgitation valve surgery is recommended. In asymptomatic patients, careful risk stratification incorporating markers of left ventricular dysfunction, atrial fibrillation, pulmonary hypertension, and valve reparability is required to identify the optimal timing of intervention.
二尖瓣脱垂(MVP)是一种常见的瓣膜病变,疾病范围从单纯脱垂到黏液瘤样、多瓣叶巴洛病。主要并发症与二尖瓣反流进展、心内膜炎、猝死和中风有关。无症状严重二尖瓣反流患者的干预时机存在争议。本文综述了二尖瓣脱垂的病理生理学、遗传学、临床特征、诊断影像学、并发症、长期预后以及干预指征。二尖瓣脱垂管理中仍存在几个关键难题。影响二尖瓣反流进展的因素尚不清楚,因此我们没有预防进展的治疗靶点。尚未确定降低猝死、中风和心内膜炎风险的循证方法。对于有症状的严重二尖瓣反流患者,建议进行瓣膜手术。对于无症状患者,需要结合左心室功能障碍、心房颤动、肺动脉高压和瓣膜可修复性标志物进行仔细的风险分层,以确定最佳干预时机。